Member Info for itsallamess

https://patents.justia.com/assignee/faron-pharmaceuticals-oy

I see we have been awarded another patent

Cell and therapeutical and diagnostical methods based thereon
Patent number: 10526607
Abstract: The invention relates to a novel cell derived from the human body, where said cell comprises a Clever-1 receptor; to a method for affecting the immune system of an individual and for treatment of diseases or conditions related to the function of the immune system and to methods for screening of cancer patients that may respond to an anti-Clever-1 therapy or for diagnosing of a pregnancy complication or for estimating the risk of such complication in a pregnant woman.
Type: Grant
Filed: March 25, 2014
Date of Patent: January 7, 2020
Assignee: FARON PHARMACEUTICALS OY
Inventors: Sirpa Jalkanen, Marko Salmi, Markku Jalkanen

If you go back to RBS titled holdings in company there was loads of IIs on board

Good to keep an eye out if these specific ones come back!

Rns Fri, 9th Dec 2016
legal & General bought 5.19% of shares

RNS Fri, 3rd Mar 2017
City Financial Investment Company Limited, acting as Investment Manager and Authorised Corporate Director of the City Financial Absolute Equity Fund bought 5.15%

Zen you are correct... The new IIs are Finnish ones who bought in on the last placing...

Question: was there any IIs who were invested before the traukamine issue and sold out?

Just relax.. You are starting to get over excited with arguing... You know we all like the peaceful gammy who contributes positive imput.

But returning to the mean sprirted gammy who abuses everyone.. No one likes!

"If anything it shows we have the right chemistry"

Unlike gammy and zen :)

Sounds slot like what we are doing... Except we are bfurthet along and we have patented ever ything.

Just shows once we get on the Rader big time we will rerate to múltiples of where we are now!

Let's see what tomorrow brings.

I'm not sure I see any strong evidence a II has been buying to today... But let's hope I'm wrong!

Zen mate.

Can you post a link where the information is that shows they have taken an interest in FARN today?

John Poulos is a Non-Executive Director for faron

Mr. Poulos is currently an Operating Partner with Linden Capital Partners, a private equity firm focused exclusively on healthcare.

He also has negotiated over 100 partnerships

Check out John Poulos’ profile on LinkedIn https://www.linkedin.com/in/john-poulos-a871a59

"Linden Capital Partners is a Chicago-based private equity firm focused exclusively on leveraged buyouts in the healthcare and life sciences industries.

Linden’s strategy is based upon...... strategic relationships with large corporations.

Linden invests in middle market platforms in the medical products, specialty distribution, pharmaceutical, and services segments of healthcare"

John Poulos is a Non-Executive Director for faronMr. Poulos is currently an Operating Partner with Linden Capital Partners, a private equity firm focused exclusively on healthcare.He also has negotiated over 100 partnershipsCheck out John Poulos’ profile on LinkedIn https://www.linkedin.com/in/john-poulos-a871a59"Linden Capital Partners is a Chicago-based private equity firm focused exclusively on leveraged buyouts in the healthcare and life sciences industries. Linden’s strategy is based upon...... strategic relationships with large corporations. Linden invests in middle market platforms in the medical products, specialty distribution, pharmaceutical, and services segments of healthcare"

https://www.linkedin.com/posts/forendo-pharma-ltd_exciting-new-collaboration-starting-with-activity-6610437785008513024-Fom7

Matti Karvonen our Chief Medical Officer likes a partnership agreement between Forendo pharma and the swiss big pharma companyNovartis International AG which had a revenue of 51.9 billion

https://www.linkedin.com/posts/faron_news-and-press-releases-activity-6610428910872084480-8tBN

Interesting comment from Yrjö E K Wichmann
VP, funding and IR, Faron Pharmaceuticals Oy
"It seems that Clevegen, our immuno-oncology candidate, does what we have anticipated. The surpricing fact is how broad its impact is. Exciting times ahead"

https://www.linkedin.com/posts/faron_new-video-available-clevegen-mode-of-action-ugcPost-6621364497632247810-8-rR

https://ukinvestormagazine.co.uk/faron-pharmaceuticals-win-approval-from-matins-trial-data-monitoring-committee-for-clevegen/

This is happening while we sit here!

Great news

Morning all

All seems a bit quite here which isn't the case with the company.

On going Attribution process with the old manufacting company for traukamine

Minutes from the FDA traukamine meeting expected with a date to start phase 3 re trial

Clevegen expanition trial

Clevegen other types of cancer trails

There is a lot going on!

I think it would be good form to get a RNS from the BOD outlining progress here.

Unfortunity I feel we all have been had and we will never relistf

So it's been moved to a undisclosed date in the future? Not even a quarter time given!

Have you sold out again gammy?